Company profile
NovAccess Global Inc.
OTC: XSNX · Healthcare · Biotechnology
#1161 of 1,418 Healthcare companies by revenue
EA Score
——FH —DQ 46GM —SS 36
v0.1 · 25/100 weight · pillars only
↑ listing tenure, disclosure history · ↓ return on assets, Piotroski F
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$2.7M
Employees
2
as of 2026-08-30
Market cap
$12.3k
as of 2026-08-30
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02024
Net income-$2.7M-$2.7M2024
Operating income-$901.7k-$901.7k2024
Total assets$62.2k$62.2k2024
Liabilities$10.1M$10.1M2024
Equity-$10.0M-$10.0M2024
Revenue trend
FY2016 – FY2024 · USD
FY16
FY17
FY18
FY19
FY20
FY23
FY23
FY24
Revenue by segment
Filed disclosures · FY2019
By product
Commercial94%
Residential5%
Management Fees1%
By geography
Not disclosed.
The read
What is NovAccess Global Inc.’s revenue?
NovAccess Global Inc. booked $0 in FY2024 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Golden Developing Solutions, Inc.——CNBX Pharmaceuticals Inc.19DVaxxinity, Inc.——VIA Pharmaceuticals, Inc.——OneLife Technologies Corp.——CardioGenics Holdings Inc——Neighbors
Geauga →Key facts
CEODwain K. Morris-Irvin
SectorHealthcare
IndustryBiotechnology
HeadquartersChesterland, OH
ExchangeOTC: XSNX
Employees2
IPO date1998-09-21
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.